Pre-market Hot Trades in US Stocks
Insmed is down 20.04% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 17, Insmed announced that its Brensocatib drug failed to meet primary or secondary efficacy endpoints in a Phase 2 study for patients with chronic sinusitis, leading to the immediate termination of the project. This news caused the stock price to drop 17% in after-hours trading. Source: MT Newswires
</li>
<li>
On December 17, Insmed announced the acquisition of INS1148, a monoclonal antibody targeting respiratory and immune inflammatory diseases. Although this move demonstrates the company's expansion plans in other areas, it failed to offset the negative impact of the Brensocatib project termination. Source: MT Newswires
</li>
<li>
On December 16, analysts Olivia Brayer and Ritu Baral assigned buy ratings to Insmed, with target prices of $230 and $241, respectively. However, the market reacted more strongly to the failure of the Brensocatib project, leading to a significant drop in the stock price. Source: Cantor Fitzgerald, TD Cowen The biotechnology sector has recently experienced increased volatility, which requires attention.
</li>
</ol>
Akanda is up 19.30% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Top Gainers in Pre-market US Stocks
Sable Offshore is up 47.54% in pre-market trading. Based on recent news:
<ol>
<li>
On December 17, Sable Offshore received confirmation from PHMSA that its pipeline is classified as an interstate facility. This reclassification shifts regulatory oversight to PHMSA, connecting the Santa Ynez Unit and Pentland Station. This news is seen as a positive regulatory change, driving the stock price up.
</li>
<li>
On December 18, Roth MKM analyst Leo Mariani maintained a buy rating on Sable Offshore and set a target price of $22. The analyst's positive rating and target price boosted market confidence, further driving the stock price up.
</li>
<li>
On December 18, Sable Offshore's Las Flores pipeline system was deemed &#34;active&#34; by PHMSA. This news confirms the operational status of the pipeline and alleviates market concerns about operational disruptions, boosting investor confidence. The energy sector has performed strongly recently, with regulatory changes having a positive impact.
</li>
</ol>
Safe Pro is up 24.46% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation
Akari Therapeutics pre-market rose 21.36%. Based on recent key news:
<ol>
<li>
On December 16, Akari Therapeutics announced it secured $5 million in financing, including a registered direct offering and private placement at market pricing. This financing news boosted investor confidence, driving the stock price up.
</li>
<li>
On December 17, Akari's main candidate drug AKTX-101 targets the Trop2 receptor on cancer cells, utilizing a novel spliceosome modulator to disrupt RNA splicing within cancer cells while activating immune responses. This technological innovation has attracted market attention, further supporting the rise in stock price.
</li>
<li>
On December 16, the company detailed in its SEC filings the risk factors that could affect the realization of forward-looking statements. Despite the risks, investors remain optimistic about the company's future development, benefiting the stock price. The biotechnology industry is innovation-driven, with significant capital inflow
</li>
</ol>

INSM

AKAN

Insmed pre-market down 20.04%; Akanda pre-market up 19.30%; Sable Offshore pre-market up 47.54%; Safe Pro pre-market up 24.46%; Akari Therapeutics pre-market up 21.36%

Pre-market hot trades in US stocks: Insmed pre-market down 20.04%; Akanda pre-market up 19.30%